Good, objective piece. Salient point... Viruses mu
Post# of 148177
Quote:
Monoclonal antibodies have crashed and burned too. Although many such drugs have ended up as transformative treatments, at least 21 of them failed in Phase III trials between 2014 and 2017. One of those was developed by Regeneron for a respiratory virus in infants: After being fast-tracked by the FDA on the basis of initial, “promising” results, the drug was abandoned in 2017. The trialists surmised that the problems they encountered—including the emergence of a mutant strain of the virus—might be overcome by delivering two different antibodies at once. That’s the design of the drug now being tested for Covid-19, and the same idea yielded exciting results for Ebola last year. So fingers crossed!